HIV-1C in-House RNA-Based Genotyping Assay for Detection of Drug Resistance Mutations in Samples with Low-Level Viral Loads

References

• Sklar PA, Ward DJ, Baker RK., et al. Prevalence and clinical correlates of HIV viremia (‘blips’) in patients with previous suppression below the limits of quantification. Aids. 2002;16(15):2035–2041. doi:10.1097/00002030-200210180-00008
   PubMed Web of Science ®Google Scholar
• Tobin NH, Learn GH, Holte SE, et al. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol. 2005;79(15):9625–9634. doi:10.1128/jvi.79.15.9625-9634.2005
   PubMed Web of Science ®Google Scholar
• Bessong PO, Matume ND, Tebit DM. Potential challenges to sustained viral load suppression in the HIV treatment programme in South Africa: a narrative overview. AIDS Res Ther. 2021;18(1):1. doi:10.1186/s12981-020-00324-w
   Web of Science ®Google Scholar
• Thaker HK. HIV viral suppression in the era of antiretroviral therapy. Postgrad Med J. 2003;79(927):36. doi:10.1136/pmj.79.927.36
   Web of Science ®Google Scholar
• Jordan MR, Winsett J, Tiro A, et al. HIV Drug Resistance Profiles and Clinical Outcomes in Patients with Viremia Maintained at Very Low Levels. World Journal of AIDS. 2013;3(2):71–78. doi:10.4236/wja.2013.32010
   Google Scholar
• Li JZ, Gallien S, Do TD, et al. Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia. Antimicrob Agents Chemother. 2012;56(11):5998–6000. doi:10.1128/aac.01217-12
   PubMed Web of Science ®Google Scholar
• Swenson LC, Min JE, Woods CK, et al. HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure. AIDS. 2014;28(8):1125–1134. doi:10.1097/qad.0000000000000203
   PubMed Web of Science ®Google Scholar
• Inzaule SC, Bertagnolio S, Kityo CM, et al. The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan Africa. AIDS. 2020;34(10):1559–1566. doi:10.1097/QAD.0000000000002588
   PubMed Web of Science ®Google Scholar
• Rosemary A, Chika O, Jonathan O, et al. Genotyping performance evaluation of commercially available HIV-1 drug resistance test. PLoS One. 2018;13(6):e0198246. doi:10.1371/journal.pone.0198246
   Web of Science ®Google Scholar
• Santoro MM, Fabeni L, Armenia D, et al. Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels. Clin Infect Dis. 2014;58(8):1156–1164. doi:10.1093/cid/ciu020
   PubMed Web of Science ®Google Scholar
• Villalobos C, Ceballos ME, Ferres M, Palma C. Drug resistance mutations in proviral DNA of HIV-infected patients with low level of viremia. J Clin Virol. 2020;132:104657. doi:10.1016/j.jcv.2020.104657
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. US Department of Human and Health Services; 2022.
   Google Scholar
• Novitsky V, Zahralban-Steele M, McLane MF, et al. Long-Range HIV Genotyping Using Viral RNA and Proviral DNA for Analysis of HIV Drug Resistance and HIV Clustering. J Clin Microbiol. 2016;4:1175. doi:10.1128/JCM.00190-16
   Web of Science ®Google Scholar
• Zash R, Holmes L, Diseko M, et al. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana. N Engl J Med. 2019;381(9):827–840. doi:10.1056/NEJMoa1905230
   PubMed Web of Science ®Google Scholar
• Yang Z, Morrison R, Oates C, et al. HIV-1 Genotypic Resistance Testing on Low Viral Load Specimens Using the Abbott ViroSeq HIV-1 Genotyping System. Lab Med. 2008;39(11):671–673. doi:10.1309/lmvovu1xrb9o3jzv
   Web of Science ®Google Scholar
• Gonzalez-Serna A, Min JE, Woods C, et al. Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals. Clin Infect Dis. 2014;58(8):1165–1173. doi:10.1093/cid/ciu019
   PubMed Web of Science ®Google Scholar
• Richman DD. Editorial commentary: extending HIV drug resistance testing to low levels of plasma viremia. Clin Infect Dis. 2014;58(8):1174–1175. doi:10.1093/cid/ciu025
   Web of Science ®Google Scholar
• AIDS JUNPoH. IN DANGER: UNAIDS Global AIDS Update 2022; 2022.
   Google Scholar
• Gaolathe T, Wirth KE, Holme MP, et al. Botswana’s progress toward achieving the 2020 UNAIDS 90- 90-90 antiretroviral therapy and virological suppression goals: a population-based survey. Lancet HIV. 2016;3(5):e221–30. doi:10.1016/s2352-3018(16
   PubMed Web of Science ®Google Scholar
• Stafford MM, Laws K, Marima RL. PELBC01. Botswana achieved the Joint United Nations Programme on HIV/AIDS (UNAIDS) 95‐95‐95 targets: results from the Fifth Botswana HIV/AIDS Impact Survey (BAIS V). J Int AIDS Soc. 2022;2022:231–232.
   Google Scholar
• Society EAC. EACS Guidelines; 2018.
   Google Scholar
• services DoHaH. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV; 2019.
   Google Scholar
• WHO. Guidelines for Managing Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy; 2017.
   Google Scholar
• Rowley CF, MacLeod IJ, Maruapula D, et al. Sharp increase in rates of HIV transmitted drug resistance at antenatal clinics in Botswana demonstrates the need for routine surveillance. J Antimicrob Chemother. 2016;71(5):1361–1366. doi:10.1093/jac/dkv500
   Web of Science ®Google Scholar
• Makhema J, Wirth KE, Pretorius Holme M, et al. Universal Testing, Expanded Treatment, and Incidence of HIV Infection in Botswana. N Engl J Med. 2019;381(3):230–242. doi:10.1056/NEJMoa1812281
   PubMed Web of Science ®Google Scholar
• World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. 2nd. World Health Organization; 2016.
   Google Scholar
• Rhee SY. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 2003;31(1):298–303. doi:10.1093/nar/gkg100
   PubMed Web of Science ®Google Scholar
• Assoumou L, Charpentier C, Recordon-Pinson P, et al. Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study. J Antimicrob Chemother. 2017;72(6):1769–1773. doi:10.1093/jac/dkx042
   Web of Science ®Google Scholar
• Parczewski M, Leszczyszyn-Pynka M, Witak-Jędra M, Maciejewska K, Urbańska A. Efficacy of genotypic drug resistance testing in patients with low-level plasma HIV-1 viremia. HIV AIDS Rev. 2015;14(3):80–83. doi:10.1016/j.hivar.2015.02.001
   Google Scholar
• Mackie N, Dustan S, McClure MO, Weber JN, Clarke JR. Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viraemia. J Virol Methods. 2004;119(2):73–78. doi:10.1016/j.jviromet.2004.02.015
   Web of Science ®Google Scholar
• Bangalee A, Hans L, Steegen K. Feasibility and clinical relevance of HIV-1 drug resistance testing in patients with low-level viraemia in South Africa. J Antimicrob Chemother. 2021;76(10):2659–2665. doi:10.1093/jac/dkab220
   PubMed Web of Science ®Google Scholar
• Assoumou L, Descamps D, Yerly S, et al. Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study. J Antimicrob Chemother. 2013;68(6):1400–1405. doi:10.1093/jac/dkt033
   Web of Science ®Google Scholar
• Waters L, Mandalia S, Asboe D. Successful use of genotypic resistance testing in HIV-1-infected individuals with detectable viraemia between 50 and 1000 copies/mL. AIDS. 2006;20(5):778–779. doi:10.1097/01.aids.0000216381.37679.69
   Web of Science ®Google Scholar
• Cane PA, Kaye S, Smit E, et al. Genotypic antiretroviral drug resistance testing at low viral loads in the UK. HIV Med. 2008;9(8):673–676. doi:10.1111/j.1468-1293.2008.00607.x
   Web of Science ®Google Scholar
• Mens H, Kearney M, Wiegand A, et al. Amplifying and quantifying HIV-1 RNA in HIV infected individuals with viral loads below the limit of detection by standard clinical assays. J Vis Exp. 2011;(55):2960. doi:10.3791/2960
   Web of Science ®Google Scholar
• Hatano H, Delwart EL, Norris PJ, et al. Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS. 2010;24(16):2535–2539. doi:10.1097/QAD.0b013e32833dba03
   Web of Science ®Google Scholar
• Vancoillie L, Mortier V, Demecheleer E, et al. Drug resistance is rarely the cause or consequence of long-term persistent low-level viraemia in HIV-1-infected patients on ART. Antivir Ther. 2015;20(8):789–794. doi:10.3851/imp2966
   PubMed Web of Science ®Google Scholar
• Villahermosa ML, Thomson M, Vázquez de Parga E, et al. Improved conditions for extraction and amplification of human immunodeficiency virus type 1 RNA from plasma samples with low viral load. J Hum Virol. 2000;3(1):27–34.
   Google Scholar
• Günthard HF, Calvez V, Paredes R, et al. Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society–USA Panel. Clin Infect Dis. 2019;68(2):177–187. doi:10.1093/cid/ciy463
   PubMed Web of Science ®Google Scholar
• Dorward J, Sookrajh Y, Ngobese H, et al. Protocol for a randomised feasibility study of Point-Of-care HIV viral load testing to Enhance Re-suppression in South Africa: the POwER study. BMJ Open. 2021;11(2):e045373. doi:10.1136/bmjopen-2020-045373
   Web of Science ®Google Scholar
• Hirsch MS, Günthard HF, Schapiro JM, et al. Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: 2008 Recommendations of an International AIDS Society–USA Panel. Clin Infect Dis. 2008;47(2):266–285. doi:10.1086/589297
   PubMed Web of Science ®Google Scholar
• Cunningham S, Ank B, Lewis D, et al. Performance of the applied biosystems ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for sequence-based analysis of HIV-1 in pediatric plasma samples. J Clin Microbiol. 2001;39(4):1254–1257. doi:10.1128/jcm.39.4.1254-1257.2001
   PubMed Web of Science ®Google Scholar
• Mukaide M, Sugiura W, Matuda M, et al. Evaluation of Viroseq-HIV version 2 for HIV drug resistance. Jpn J Infect Dis. 2000;53(5):203–205.
   Web of Science ®Google Scholar
• Bareng OT, Moyo S, Zahralban-Steele M, et al. HIV-1 drug resistance mutations among individuals with low-level viraemia while taking combination ART in Botswana. J Antimicrob Chemother. 2022;77(5):1385–1395. doi:10.1093/jac/dkac056
   Web of Science ®Google Scholar
• Moyo S, Gaseitsiwe S, Zahralban-Steele M, et al. Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana. Aids. 2019;33(6):1073–1082. doi:10.1097/qad.0000000000002166
   Web of Science ®Google Scholar
• Bon I, Alessandrini F, Borderi M, Gorini R, Re MC. Analysis of HIV-1 drug-resistant variants in plasma and peripheral blood mononuclear cells from untreated individuals: implications for clinical management. New Microbiol. 2007;30(3):313–317.
   Web of Science ®Google Scholar